The potential role of iron chelators in the treatment of Parkinson's disease and related neurological disorders.

No abstract is available for this paper.

• Publication year

  1997

• Venue

  Acta Pharmacologica et Toxicologica

• Publication date

  1997-04-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1111/J.1600-0773.1997.TB00390.XPMID 9140134
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Design of Orally Active Iron Chelators

  2005cited by this paper
• Effects of chelators on iron uptake and release by the brain in the rat

  2004cited by this paper
• ‘Free’ iron, as detected by electron paramagnetic resonance spectroscopy, increases unequally in different tissues during dietary iron overload in the rat

  2004cited by this paper
• Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease.

  1996cited by this paper
• Long-term therapy with deferiprone.

  1996cited by this paper
• Cardioprotective effect of desferrioxamine.

  1996cited by this paper
• Prevention of anthracycline cardiotoxicity by iron chelation.

  1996cited by this paper
• Molecular Modeling Studies of a Ferric Hexadentate 3-Hydroxy-2(1H)-pyridinone Complex and an Analogue by Molecular Mechanics, Molecular Dynamics, and Free Energy Perturbation Simulations

  1996cited by this paper
• Nature of Inhibition of Mitochondrial Respiratory Complex I by 6‐Hydroxydopamine

  1996cited by this paper
• Use of iron chelators in preventing hydroxyl radical damage: adult respiratory distress syndrome as an experimental model for the pathophysiology and treatment of oxygen-radical-mediated tissue damage.

  1996cited by this paper
• A Quantitative Analysis of Isoferritins in Select Regions of Aged, Parkinsonian, and Alzheimer's Diseased Brains

  1995cited by this paper
• Transferrin and Iron in Normal, Alzheimer's Disease, and Parkinson's Disease Brain Regions

  1995cited by this paper
• Autoradiographic localization and density of [125I]ferrotransferrin binding sites in the basal ganglia of control subjects, patients with Parkinson's disease and MPTP-lesioned monkeys.

  1995cited by this paper
• Nitric oxide signaling to iron-regulatory protein: direct control of ferritin mRNA translation and transferrin receptor mRNA stability in transfected fibroblasts.

  1995cited by this paper
• Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease.

  1995cited by this paper
• N,N'-bis-dibenzyl ethylenediaminediacetic acid (DBED): a site-specific hydroxyl radical scavenger acting as an "oxidative stress activatable" iron chelator in vitro.

  1995cited by this paper
• Expression of lactoferrin receptors is increased in the mesencephalon of patients with Parkinson disease.

  1995cited by this paper
• Rapid responses to oxidative stress mediated by iron regulatory protein.

  1995cited by this paper
• Activated microglia cause superoxide-mediated release of iron from ferritin.

  1995cited by this paper
• Protection of cultured rat gastric cells against oxidant stress by iron chelation

  1995cited by this paper
• EPR study of antioxidant activity of the iron chelators pyoverdin and hydroxypyrid-4-one in iron-loaded hepatocyte culture: comparison with that of desferrioxamine.

  1995cited by this paper
• Hereditary haemochromatosis: a case of iron accumulation in the basal ganglia associated with a parkinsonian syndrome.

  1995cited by this paper
• Oxidative stress induces activation of a cytosolic protein responsible for control of iron uptake.

  1995cited by this paper
• Characteristics of Fe(II)ATP complex-induced damage to the rat liver mitochondrial membrane

  1995cited by this paper
• Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators.

  1994cited by this paper
• Evidence that the pathway of transferrin receptor mRNA degradation involves an endonucleolytic cleavage within the 3′ UTR and does not involve poly(A) tail shortening.

  1994cited by this paper
• Prooxidant and antioxidant properties of iron-hydroquinone and iron-1,2,4-benzenetriol complex. Implications for benzene toxicity.

  1994cited by this paper
• The enigma of neuromelanin in Parkinson's disease substantia nigra.

  1994cited by this paper
• Iron release from ferritin and its sensitivity to superoxide ions differs among vertebrates.

  1994cited by this paper
• Neuroprotective and Neurodestructive Effects of Nitric Oxide and Redox Congeners

  1994cited by this paper
• Metabolism of the cardioprotective agents dexrazoxane (ICRF-187) and levrazoxane (ICRF-186) by the isolated hepatocyte.

  1994cited by this paper
• Non-haem iron histochemistry of the normal and Alzheimer's disease hippocampus.

  1994cited by this paper
• Altered Brain Metabolism of Iron as a Cause of Neurodegenerative Diseases?

  1994cited by this paper
• Typical and Atypical Neuroleptics Induce Alteration in Blood‐Brain Barrier and Brain 59FeCl3 Uptake

  1994cited by this paper
• Ferritin stimulation of hydroxyl radical production by rat liver nuclei.

  1994cited by this paper
• Blood to brain iron uptake in one rhesus monkey using [Fe-52]-citrate and positron emission tomography (PET): influence of haloperidol.

  1994cited by this paper
• The role of iron and iron chelators in anthracycline cardiotoxicity.

  1993cited by this paper
• The effect of a synthetic hexadentate iron chelator (CP130) and desferrioxamine on rabbit kidneys exposed to cold and warm ischaemia

  1993cited by this paper
• MR detection of brain iron.

  1993cited by this paper
• Iron modulates neuroleptic-induced effects related to the dopaminergic system.

  1993cited by this paper
• Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain

  1993cited by this paper
• Lazaroids: potent inhibitors of iron-dependent lipid peroxidation for neurodegenerative disorders

  1993cited by this paper
• Brain iron: location and function.

  1993cited by this paper
• The possible role of iron in the etiopathology of parkinson's disease

  1993cited by this paper
• The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls

  1993cited by this paper
• Antioxidant and iron-chelating activities of the flavonoids catechin, quercetin and diosmetin on iron-loaded rat hepatocyte cultures.

  1993cited by this paper
• Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia. The Royal Kings and Queens Parkinson's Disease Research Group.

  1992cited by this paper
• Antioxidant and free radical scavenging activities of the iron chelators pyoverdin and hydroxypyrid-4-ones in iron-loaded hepatocyte cultures: comparison of their mechanism of protection with that of desferrioxamine.

  1992cited by this paper
• Role of iron and iron chelation in dopaminergic‐induced neurodegeneration: Implication for Parkinson's disease

  1992cited by this paper
• Alterations in levels of iron, ferritin, and other trace metals in neurodegenerative diseases affecting the basal ganglia

  1992cited by this paper
• Iron regulation in the brain: Histochemical, biochemical, and molecular considerations

  1992cited by this paper
• Iron accumulation in the rat basal ganglia after excitatory amino acid injections--dissociation from neuronal loss.

  1992cited by this paper
• Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease

  1992cited by this paper
• Regional distribution of iron and iron‐regulatory proteins in the brain in aging and Alzheimer's disease

  1992cited by this paper
• Intranigral Iron Injection Induces Behavioral and Biochemical “Parkinsonism” in Rats

  1991cited by this paper
• Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.

  1991cited by this paper
• Distribution and number of transferrin receptors in Parkinson's disease and in MPTP-treated mice.

  1991cited by this paper
• Iron‐Melanin Interaction and Lipid Peroxidation: Implications for Parkinson's Disease

  1991cited by this paper
• The impact of varying degrees of iron nutriture on several functional consequences of iron deficiency in rats.

  1991cited by this paper
• Iron in brain function and dysfunction with emphasis on Parkinson's disease.

  1991cited by this paper
• Selective Increase of Iron in Substantia Nigra Zona Compacta of Parkinsonian Brains

  1991cited by this paper
• Experimental studies on the mechanism of action of 4‐Hydroxy‐2,3‐trans‐nonenal, a lipid peroxidation product displaying chemotactic activity toward rat neutrophils

  1991cited by this paper
• Mechanism of protection of alveolar type II cells against paraquat-induced cytotoxicity by deferoxamine.

  1990cited by this paper
• Selectivity of melaninized nigra-striatal dopamine neurons to degeneration in Parkinson's disease may depend on iron-melanin interaction.

  1990cited by this paper
• Normal deposition of brain iron in childhood and adolescence: MR imaging at 1.5 T.

  1989cited by this paper
• Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

  1989cited by this paper
• Biochemical fundamentals of Parkinson's disease.

  1988cited by this paper
• The role of iron in the initiation of lipid peroxidation.

  1987cited by this paper
• Metal ions and oxygen radical reactions in human inflammatory joint disease.

  1985cited by this paper
• Effect of Iron Chelators on Dopamine D2 Receptors

  1985cited by this paper
• Oxygen radicals and the nervous system

  1985cited by this paper
• Cerebral and ocular toxicity induced by desferrioxamine.

  1985cited by this paper
• Manifestation of iron deficiency at various levels of dietary iron intake.

  1980cited by this paper

• The J bs-5YP peptide can alleviate dementia in senile mice by restoring the transcription of Slc40a1 to secrete the excessive iron from brain

  2024cites this paper
• The bs-YHEDA peptide protects the brains of senile mice and thus recovers intelligence by reducing iron and free radicals.

  2022cites this paper
• Ketogenic diet prevents chronic sleep deprivation-induced Alzheimer’s disease by inhibiting iron dyshomeostasis and promoting repair via Sirt1/Nrf2 pathway

  2022cites this paper
• Neuroprotection and Neurorestoration of Nigra Striatal Dopamine Neurons by Novel Multitarget Drugs, M30

  2021cites this paper
• Lipocalin 2 regulates iron homeostasis, neuroinflammation, and insulin resistance in the brains of patients with dementia: Evidence from the current literature

  2021cites this paper
• Nutraceuticals: An integrative approach to starve Parkinson’s disease

  2020cites this paper
• TO STUDY THEANTIOXIDANT EFFECT OF BRAHMI ON CATALASE AND GSH ACTIVITIY.

  2019cites this paper
• Using the synthesized peptide HAYED (5) to protect the brain against iron catalyzed radical attack in a naturally senescence Kunming mouse model

  2019cites this paper
• Linking the low-density lipoprotein receptor-binding segment enables the therapeutic 5-YHEDA peptide to cross the blood-brain barrier and scavenge excess iron and radicals in the brain of senescent mice

  2019cites this paper
• 5-HAYED peptide can protect AD brain by scavenging the redundant iron ions and the catalyzed radicals

  2018cites this paper
• The synthesized transporter K16APoE enabled the therapeutic HAYED peptide to cross the blood-brain barrier and remove excess iron and radicals in the brain, thus easing Alzheimer’s disease

  2018cites this paper
• Preclinical and Potential Applications of Common Western Herbal Supplements as Complementary Treatment in Parkinson's Disease

  2017cites this paper
• Antioxidant and free radical scavenging properties of Arictum lappa

  2017cites this paper
• Tridentate (O,N,O) ligands as potential chelator compounds for iron overload

  2017cites this paper
• EVALUATION OF ANTIOXIDANT ACTIVITY OF PHYLLANTHUS ACIDUS

  2016cites this paper
• Elucidation of the interplay between Fe(II), Fe(III), and dopamine with relevance to iron solubilization and reactive oxygen species generation by catecholamines

  2016cites this paper
• Metals, oxidative stress and neurodegeneration: a focus on iron, manganese and mercury.

  2013cites this paper
• Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats.

  2013cites this paper
• IN VITRO ASSESSMENT OF ANTIBACTERIAL AND ANTIOXIDANT ACTIVITIES OF FRUIT RIND EXTRACTS OF GARCINIA CAMBOGIA. L.

  2013cites this paper
• Therapeutic benefits from nanoparticles: the potential significance of nanoscience in diseases with compromise to the blood brain barrier.

  2013cites this paper
• Catechin attenuates behavioral neurotoxicity induced by 6-OHDA in rats

  2013cites this paper
• 1B/(−)IRE DMT1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NF-κB/RelA Acetylation at Lys310

  2012cites this paper
• Nanoparticle delivery of transition-metal chelators to the brain: Oxidative stress will never see it coming!

  2012cites this paper
• Biological activities of extract of Anthemis aetnensis Schouw: In vitro evaluation

  2012influential citation
• 1 B / ( 2 ) IRE DMT 1 Expression during Brain Ischemia Contributes to Cell Death Mediated by NFk B / RelA Acetylation at Lys 310

  2012cites this paper
• Int. J. Biosci

  2012cites this paper
• Neuroprotective Multifunctional Iron Chelators: From Redox-Sensitive Process to Novel Therapeutic Opportunities

  2010cites this paper
• Nanoparticle and iron chelators as a potential novel Alzheimer therapy.

  2010cites this paper
• Iron and reactive oxygen species activity in parkinsonian substantia nigra.

  2010cites this paper
• Natural polyphenols as anti-inflammatory agents

  2009cites this paper
• Metal chelators coupled with nanoparticles as potential therapeutic agents for Alzheimer's disease.

  2009cites this paper
• SYSTEMIC ADMINISTRATION OF Zn2+ DURING THE REPERFUSION PHASE OF TRANSIENT CEREBRAL ISCHAEMIA PROTECTS RAT HIPPOCAMPUS AGAINST IRON‐CATALYSED POSTISCHAEMIC INJURY

  2008cites this paper
• FORMALDEHYDE-INDUCED DAMAGE IN LUNGS AND EFFECTS OF CAFFEIC ACID PHENETHYL ESTER: A LIGHT MICROSCOPIC STUDY

  2008cites this paper
• Nanoparticles for the Treatment of Alzheimer's Disease: Theoretical Rationale, Present Status and Future Perspectives

  2007cites this paper
• Role of Iron in Neurodegenerative Disorders

  2006cites this paper
• Blood donations, iron stores, and risk of Parkinson's disease

  2006cites this paper
• Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload.

  2006cites this paper
• M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

  2006cites this paper
• X‐ray fluorescence microprobe imaging in biology and medicine

  2006cites this paper
• Metal complexes of maltol and close analogues in medicinal inorganic chemistry.

  2006cites this paper
• Antioxidant and Free Radical Scavenging Properties of Twelve Traditionally Used Indian Medicinal Plants

  2006cites this paper
• Iron dysregulation and Parkinson's disease

  2005cites this paper
• Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

  2005cites this paper
• Free Radical Scavenging Activity of Linum arboreum.

  2005cites this paper
• Novel multifunctional neuroprotective iron chelator‐monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition

  2005cites this paper
• Nanoparticle and other metal chelation therapeutics in Alzheimer disease.

  2005cites this paper
• Iron chelators in cancer chemotherapy.

  2004cites this paper
• Ethanol-induced oxidative stress in rat astrocytes: role of HSP70

  2004cites this paper
• Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson’s disease and other neurodegenerative diseases

  2004cites this paper
• Bioflavonoids as antiradicals, antioxidants and DNA cleavage protectors

  2004cites this paper
• Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases

  2004cites this paper
• Cell signaling pathways in the neuroprotective actions of the green tea polyphenol (‐)‐epigallocatechin‐3‐gallate: implications for neurodegenerative diseases

  2004cites this paper
• Ironing Iron Out in Parkinson's Disease and Other Neurodegenerative Diseases with Iron Chelators: A Lesson from 6‐Hydroxydopamine and Iron Chelators, Desferal and VK‐28

  2004cites this paper
• Antioxidant activity and protective effect on DNA cleavage of extracts from Cistus incanus L. and Cistus monspeliensis L.

  2004cites this paper
• Free radical scavenging capacity and protective effect of Bacopa monniera L. on DNA damage

  2003cites this paper
• Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease.

  2003cites this paper
• Cyanidin and cyanidin 3-O-β-D-glucoside as DNA cleavage protectors and antioxidants

  2003cites this paper
• The role of iron chelation in cancer therapy.

  2003cites this paper
• Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin.

  2002cites this paper
• Pyridoxal isonicotinoyl hydrazone and its analogues.

  2002cites this paper
• Red Orange Extract: Effect on DNA Cleavage

  2002cites this paper
• Antioxidant property of Celastrus paniculatus willd.: a possible mechanism in enhancing cognition.

  2002cites this paper
• Antioxidant Activity and Protective Effect on DNA Cleavage of Resveratrol

  2002cites this paper
• Comparative effects of metal chelating agents on the neuronal cytotoxicity induced by copper (Cu+2), iron (Fe+3) and zinc in the hippocampus.

  2001cites this paper
• Green tea polyphenol (–)‐epigallocatechin‐3‐gallate prevents N‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐induced dopaminergic neurodegeneration

  2001cites this paper
• Neonatal iron potentiates adult MPTP-induced neurodegenerative and functional deficits.

  2001cites this paper
• Heme oxygenase-1 (HSP-32) and heme oxygenase-2 induction in neurons and glial cells of cerebral regions and its relation to iron accumulation after focal cortical photothrombosis.

  2001cites this paper
• Indian medicinal plants as antiradicals and DNA cleavage protectors.

  2001cites this paper
• The iron chelator pyridoxal isonicotinoyl hydrazone inhibits mitochondrial lipid peroxidation induced by Fe(II)-citrate.

  2001cites this paper
• Oxidative stress indices in Parkinson's disease : biochemical determination.

  2001cites this paper
• Recent advances in the design of iron chelators against oxidative damage.

  2001cites this paper
• Contribution of Intracellular Non-Haem Iron, NF-kB Activation and Inflammatory Responses to Neurodegeneration in Parkinson’s Disease: Prospects for Neuroprotection

  2000cites this paper
• Sodium Azide-Induced Neurotoxicity

  2000cites this paper
• Measurement of loosely-bound iron in brain regions using redox cycling and salicylate.

  2000cites this paper
• Neuroprotective Strategies in Parkinson's Disease Using the Models of 6‐Hydroxydopamine and MPTP a

  2000cites this paper
• Neurotoxic Factors in Parkinson’s Disease and Related Disorders

  2000cites this paper
• Iron as a vulnerability factor in nigrostriatal degeneration in aging and Parkinson's disease.

  2000cites this paper
• Protection against oxidative damage by iron chelators: effect of lipophilic analogues and prodrugs of N,N'-bis(3,4,5-trimethoxybenzyl)ethylenediamine- N,N'-diacetic acid (OR10141).

  2000cites this paper
• Neurotoxic relationship between dopamine and iron in the striatal dopaminergic nerve terminals.

  2000cites this paper
• MPTP and 6-hydroxydopamine-induced neurodegeneration as models for Parkinson’s disease: neuroprotective strategies

  2000cites this paper
• The interaction of Rubia cordifolia with iron redox status: a mechanistic aspect in free radical reactions.

  1999cites this paper
• The Role of Iron in Neurodegeneration

  1999cites this paper
• The Role of Iron in Parkinson Disease and 1‐Methyl‐4‐Phenyl‐1,2,3,6‐Tetrahydropyridine Toxicity

  1999cites this paper
• Effets pro- et antioxydants de l'ascorbate

  1999cites this paper
• Protection from Oxidative Stress–Induced Apoptosis in Cortical Neuronal Cultures by Iron Chelators Is Associated with Enhanced DNA Binding of Hypoxia-Inducible Factor-1 and ATF-1/CREB and Increased Expression of Glycolytic Enzymes, p21waf1/cip1, and Erythropoietin

  1999cites this paper
• Protection of U937 cells against oxidative injury by a novel series of iron chelators.

  1998cites this paper
• Ocular Oxidants and Antioxidant Protection

  1998cites this paper
• [The molecular basis of neurodegenerative processes in the central nervous system].

  1998cites this paper
• Effects of cytisine on hydroxyl radicals in vitro and MPTP-induced dopamine depletion in vivo.

  1998cites this paper
• Advances in Supramolecular Chemistry

  1997cites this paper